SRPT Stock Analysis: Buy, Sell, or Hold?
SRPT - Sarepta Therapeutics,, Inc. Common Stock
$14.86
-0.70 (-4.50%)
▼
5d:
-5.23%
30d:
-18.35%
90d:
-28.83%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
2d
Smart Money Distribution
None View Scanner →
Strength: 7.6/10
Get Alerted When SRPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SRPT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SRPT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.96
Based on -22.4% avg growth
INTRINSIC VALUE TODAY
$2.46
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SRPT is currently trading at $14.86, which is considered oversold relative to its 30-day fair value range of $15.79 to $18.84. The stock's valuation (Forward PE: 6.1) is in line with its historical norms (6.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.2% over the next few years. This pessimistic expectation contrasts with the company's recent 2663.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $14.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $22.17 (+49.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $14.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $22.17 (+49.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$15.79 -
$18.84
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding SRPT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 49.2% below Wall St target ($22.17)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$15.79 -
$18.84
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.84
Resistance Level
$17.70
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.07
Wall Street Target
$22.17
(+49.2%)
Revenue Growth (YoY)
-1.9%
Earnings Growth (YoY)
2663.8%
Profit Margin
3.0%
Valuation Discount vs History
-3.2% cheaper
PE vs Historical
6.1 vs 6.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.2%
(market-implied from PE analysis)
1-Year Target
$14.38
(-3%)
2-Year Target
$13.92
(-6%)
3-Year Target
$13.48
(-9%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$14.88
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: -48.8%)
$36.99
(+149%)
Base:
(SPY PE: 6.1, Growth: -48.8%)
$10.83
(-27%)
Bear:
(PE: 5.2, Growth: -48.8%)
$9.21
(-38%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (44x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 44.46 | Current EPS (TTM): $0.35
Bull Case
$34.23
(+130%)
Analyst growth 100.0%, PE expands to 48.9
Base Case
$31.12
(+109%)
Market implied 100.0%, PE stable at 44.5
Bear Case
$10.58
(-29%)
Severe decline -20.0%, PE contracts to 37.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.1 to 6.7
Stabilization Target:
$16.40
(+10.4%)
PE Expansion Potential:
+10.4%
Share & Embed Analysis
Last updated: August 02, 2026 2:11 PM ET
Data refreshes hourly during market hours. Next update: 3:11 PM
Data refreshes hourly during market hours. Next update: 3:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Stephen Mayo
SELL
7239 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
Advanced SRPT Option Strategies
Professional options setups generated by AI based on today's SRPT price and gamma walls.
